The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Open accessAbstract
BACKGROUND: Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter (4.0 mmol per liter) and 2000 mg per deciliter (22.6 mmol per liter) (ISIS 304801 monotherapy cohort), as well as in patients receiving stable fibrate therapy who had fasting triglyceride levels between 225 mg per deciliter (2.5 mmol per liter) and 2000 mg per deciliter (ISIS 304801-fibrate cohort). Eligible patients were randomly assigned to receive either ISIS 304801, at doses ranging from 100 to 300 mg, or placebo, once weekly for 13 weeks. The primary outcome was the percentage change in APOC3 level from baseline. RESULTS: A total of 57 patients were treated in the ISIS 304801 monotherapy cohort (41 received active agent, and 16 received placebo), and 28 patients were treated in the ISIS 304801-fibrate cohort (20 received active agent, and 8 received placebo). The mean (±SD) baseline triglyceride levels in the two cohorts were 581±291 mg per deciliter (6.6±3.3 mmol per liter) and 376±188 mg per deciliter (4.2±2.1 mmol per liter), respectively. Treatment with ISIS 304801 resulted in dose-dependent and prolonged decreases in plasma APOC3 levels when the drug was administered as a single agent (decreases of 40.0±32.0% in the 100-mg group, 63.8±22.3% in the 200-mg group, and 79.6±9.3% in the 300-mg group, vs. an increase of 4.2±41.7% in the placebo group) and when it was administered as an add-on to fibrates (decreases of 60.2±12.5% in the 200-mg group and 70.9±13.0% in the 300-mg group, vs. a decrease of 2.2±25.2% in the placebo group). Concordant reductions of 31.3 to 70.9% were observed in triglyceride levels. No safety concerns were identified in this short-term study. CONCLUSIONS: We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a randomized, placebo-controlled, double-blind phase 2 trial of 57 patients with elevated triglycerides, volanesorsen reduced ApoC-III by up to − 80% and triglycerides by − 71% [175].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen is an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA) and reduces plasma apolipoprotein C-III levels, as well as the degree of chylomicronemia and plasma triglyceride levels.”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen (previously known as ISIS-APOC-III RX ) is a second-generation ASO developed to inhibit apoCIII”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [170]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen, a second-generation antisense oligonucleotide (ASO) targeting hepatic APOC3 mRNA, has shown the capacity to lower TG by up to 77% in patients with Familial chylomicronemia syndrome (FCS) [114]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several miRNAs and antisense oligonucleotides (ASOs) are currently under investigation in clinical trials for various diseases (Kanasty et al., 2013;van Rooij and Kauppinen, 2014;Gaudet et al., 2015).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Gaudet et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The agent has been approved in the European Union and the United Kingdom for the treatment of familial chylomicronemia syndrome and in Brazil for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. 23-25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“In a Phase 2 trial of volanesorsen, 300 mg given weekly to HTG patients (NCT01529424), TG levels were reduced by 80%.68”
From Clinical review on triglycerides (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Research works printed but not linked: 1
- Brunzell JD, 1973, Trans Assoc Am Physicians, 86, 245
Cited by
Sorted by citations
Items 201–300 of 530
Hsueh, W.-C., Nair, A. K., Kobes, S., Chen, P., Göring, H. H. H., Pollin, T. I., Malhotra, A., Knowler, W. C., Baier, L. J., & Hanson, R. L. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001809 · Cited by 32
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Kockx, M., Glaros, E. N., Leung, B., Ng, T. W., Berbée, J. F. P., Deswaerte, V., Nawara, D., Quinn, C. M., Rye, K., Jessup, W., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.307030 · Cited by 32
Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease
Lamprea-Montealegre, J. A., McClelland, R. L., Grams, M. E., Ouyang, P., Szklo, M., & de Boer, I. H. (2018) · Heart · doi:10.1136/heartjnl-2017-312794 · Cited by 33
Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury
Schunk, S. J., Hermann, J., Sarakpi, T., Triem, S., Lellig, M., Hahm, E., Zewinger, S., Schmit, D., Becker, E., Möllmann, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040503 · Cited by 31
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
RNA therapeutics for cardiovascular disease
Boada, C., Sukhovershin, R. A., Pettigrew, R. I., & Cooke, J. P. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000850 · Cited by 31
Decoding microRNA drivers in atherosclerosis
Vartak, T., Kumaresan, S., & Brennan, E. P. (2022) · Bioscience Reports · doi:10.1042/bsr20212355 · Cited by 29
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Lomitapide for the treatment of hypertriglyceridemia
Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 29
Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction
Mishra, M. K., Loro, E., Sengupta, K., Wilton, S. D., & Khurana, T. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182676 · Cited by 29
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Bchetnia, M., Bouchard, L., Mathieu, J., Campeau, P. M., Morin, C., Brisson, D., Laberge, A., Vézina, H., Gaudet, D., & Laprise, C. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-107809 · Cited by 40
Self-citationLi, D., Rodia, C. N., Johnson, Z. K., Bae, M., Muter, A., Heussinger, A. E., Tambini, N. S., Longo, A. M., Dong, H., Lee, J., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m092460 · Cited by 29
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 33
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 31
Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients
Khoonsari, P. E., Musunri, S., Herman, S., Svensson, C. I., Tanum, L., Gordh, T., & Kultima, K. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.014 · Cited by 28
Hu, S., Cui, G., Huang, J., Jiang, J.-G., & Wang, D. W. (2016) · Scientific Reports · doi:10.1038/srep32700 · Cited by 29
Lightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 27
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
Martinelli, N., Baroni, M., Castagna, A., Lunghi, B., Stefanoni, F., Tosi, F., Croce, J., Udali, S., Woodhams, B. J., Girelli, D., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676817 · Cited by 27
Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction
Hastings, M. L., & Brigande, J. V. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107931 · Cited by 27
Drenos, F., Smith, G. D., Ala‐Korpela, M., Kettunen, J., Würtz, P., Soininen, P., Kangas, A. J., Dale, C. E., Lawlor, D. A., Gaunt, T. R., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001302 · Cited by 26
Lumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 26
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 26
Increasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Wierzbicki, A. S. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch44 · Cited by 26
Sahebkar, A., Simental‐Mendía, L. E., Katsiki, N., Reiner, Ž., Banach, M., Pirro, M., & Atkin, S. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021508 · Cited by 25
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 28
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 26
Orsi, F. A., Lijfering, W. M., van der Laarse, A., Ruhaak, L. R., Rosendaal, F. R., Cannegieter, S. C., & Cobbaert, C. M. (2019) · Clinical Epidemiology · doi:10.2147/clep.s196266 · Cited by 24
D’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 24
Rabacchi, C., D’Addato, S., Palmisano, S., Lucchi, T. A., Bertolini, S., Calandra, S., & Tarugi, P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.03.009 · Cited by 24
Butler, A. A., Price, C. A., Graham, J. L., Stanhope, K. L., King, S. M., Hung, Y.-H., Sethupathy, P., Wong, S. C., Hamilton, J., Krauss, R. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089508 · Cited by 25
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan, D. C., & Watts, G. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000920 · Cited by 24
Miguel, A., Sendra, L., Noé, V., Ciudad, C. J., Dası́, F., Hervás, D., Herrero, M. J., & Aliño, S. F. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104393 · Cited by 23
GWAS Reveal Targets in Vessel Wall Pathways to Treat Coronary Artery Disease
Turner, A. W., Wong, D., Dreisbach, C., & Miller, C. L. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00072 · Cited by 24
Kim, E. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5758 · Cited by 31
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 22
Ramms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 22
Self-citationSathiyakumar, V., Pallazola, V. A., Park, J., Vakil, R. M., Toth, P. P., Lazo, M., Quispe, R., Güallar, E., Banach, M., Blumenthal, R. S., et al. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.86964 · Cited by 21
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez‐Martínez, P., Mora, S., Bilianou, H. I., Panotopoulos, G., Katsiki, N., Ooi, T. C., López‐Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190503123911 · Cited by 23
Emerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
Genomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 22
Towards more specific treatment for diabetic dyslipidemia
Rodriguez, V., Newman, J. D., & Schwartzbard, A. Z. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000528 · Cited by 21
The role of patient registries for rare genetic lipid disorders
Ng, D., Hooper, A. J., Bellgard, M., & Burnett, J. R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000485 · Cited by 20
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22
HDL-cholesterol, genetics, and coronary artery disease: the myth of the ‘good cholesterol’?
Landmesser, U., & Hazen, S. L. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy299 · Cited by 20
Gene-based therapies in lipidology
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
Self-citationApoprotein C-III: A review of its clinical implications
Jin, J., Guo, Y., & Li, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.016 · Cited by 21
Wiesner, P., & Watson, K. E. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.004 · Cited by 21
New approaches to address dyslipidemia
Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 19
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Buckner, T., Shao, B., Eckel, R. H., Heinecke, J. W., Bornfeldt, K., & Snell‐Bergeon, J. K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.10.006 · Cited by 20
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 21
Self-citationKarwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Self-citationGirelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18
Triglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 20
Feingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Sigfrids, F. J., Stechemesser, L., Dahlström, E. H., Forsblom, C. M., Harjutsalo, V., Weitgasser, R., Taskinen, M., Groop, P., & the FinnDiane Study Group (2021) · Journal of Internal Medicine · doi:10.1111/joim.13412 · Cited by 17
Etiology and emerging treatments for familial chylomicronemia syndrome
Spagnuolo, C. M., & Hegele, R. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365787 · Cited by 17
Koch, M., Furtado, J. D., Jiang, Z. G., Gray, B. E., Cai, T., Sacks, F. M., Tjønneland, A. M., Overvad, K., & Jensen, M. K. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p073288 · Cited by 17
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Doi, T., Nordestgaard, B. G., & Langsted, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000799 · Cited by 17
VLDL receptor gene therapy for reducing atherogenic lipoproteins
Krauss, R. M., Lu, J. T., Higgins, J. J., Clary, C. M., & Tabibiazar, R. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101685 · Cited by 18
Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA
Sinari, S. A., Koška, J., Hu, Y., Furtado, J. D., Jensen, M. K., Budoff, M. J., Nedelkov, D., McClelland, R. L., Billheimer, D. D., & Reaven, P. D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319035 · Cited by 16
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 17
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationInferring Half-Lives at the Effect Site of Oligonucleotide Drugs
Jansson‐Löfmark, R., & Gennemark, P. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0739 · Cited by 17
The Medicinal Chemistry of RNase H-activating Antisense Oligonucleotides
Seth, P. P., & Swayze, E. E. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00032 · Cited by 16
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 18
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01293-9 · Cited by 16
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 16
Olkowicz, M., Czyżyńska-Cichoń, I., Szupryczyńska, N., Kostogrys, R. B., Kochan, Z., Dȩbski, J., Dadlez, M., Chłopicki, S., & Smolenski, R. T. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02663-8 · Cited by 16
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Zuzda, K., Grycuk, W., Małyszko, J. S., & Małyszko, J. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2161887 · Cited by 16
de Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 15
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 15
Self-citationManagement of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children
Poon, S. W.-Y., Leung, K. K. Y., & Tung, J. Y. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0052 · Cited by 16
Kuthiroly, S., Yesodharan, D., Radhakrishnan, N., Ganapathy, A., Mannan, A. U., Hoffmann, M. M., & Nampoothiri, S. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03305-z · Cited by 15
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 15
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15
Triglyceride Treatment in the Age of Cholesterol Reduction
Agrawal, N., Corradi, P. F., Gumaste, N., & Goldberg, I. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.003 · Cited by 15
Maraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 16
Wagner, R., Dittrich, J., Thiery, J., Ceglarek, U., & Burkhardt, R. (2019) · Journal of Lipid Research · doi:10.1194/jlr.d084301 · Cited by 15
Is hypertriglyceridemia atherogenic?
Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15
Targeting RNA to lower triglycerides: long strides from short molecules
Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14
Metadata
- Authors
- Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell, J. D., & Kastelein, J. J. P.
- Affiliations
- University of Washington (US)
- Ionis Pharmaceuticals (United States) (US)
- Université de Montréal (CA)
- University of California San Diego (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-30
- Volume
- 373
- Issue
- 5
- Pages
- 438-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315899065
- Semantic Scholar
- b8b4f0ae969760d3373ca1d9082abfee85fe16d9
- Cited by
- 528
- References
- 51
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 27 · 2023: 32 · 2022: 51 · 2021: 46 · 2020: 63 · 2019: 61 · 2018: 68 · 2017: 58 · 2016: 58 · 2015: 13
- FWCI
- 47.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, fibrate therapy, dose-ranging, cardiovascular risk, pancreatitis risk, triglyceride metabolism, monotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Oligonucleotides, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
